Phase I/II Trial of AZD6750, CD8-guided IL-2 fusion protein, in advanced solid tumors

This trial evaluates the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of AZD6750 as a single agent or in combination with rilvegostomig—a Tigit and PD-1 bispecific mAb—in adult participants with select advanced or metastatic solid tumors including TNBC, melanoma, and NSCLC. Led by AstraZeneca, it represents a first-in-human investigation of a novel IL-2 engineered immune activator. Current immunotherapy SoC uses PD-1/PD-L1 ± CTLA-4; engineered IL-2 aims to expand effector CD8s with fewer high-dose-IL-2 toxicities and potentially deepen checkpoint responses.